All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC

February 15th 2025

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC

February 15th 2025

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC

February 15th 2025

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC

February 15th 2025

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

1.34-mg Dose of Tivozanib Is More Efficacious Than Reduced 0.89-mg Dose in RCC

February 15th 2025

An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status

February 15th 2025

Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.

Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer

February 15th 2025

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer

February 15th 2025

Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

February 14th 2025

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

February 14th 2025

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment

February 14th 2025

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC

February 14th 2025

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions

February 14th 2025

Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor

February 14th 2025

The FDA has approved vimseltinib for the treatment of patients with tenosynovial giant cell tumor.